Summary
Abbott Laboratories reported strong financial performance for the second quarter and first half of 2008, with net sales increasing by 14.8% and 14.3% respectively compared to the prior year. This growth was driven by robust performance across its key segments, particularly Pharmaceuticals and Diagnostics. The company also benefited from favorable foreign currency exchange rates. A significant event during the quarter was the conclusion of the TAP Pharmaceutical Products Inc. joint venture, where Abbott acquired the Lupron business, leading to the recognition of substantial intangible assets and goodwill. The company generated substantial operating earnings and net earnings, with diluted EPS at $0.85 for the quarter and $1.45 for the six-month period. The company also continued its share repurchase program and maintained a strong liquidity position with substantial cash and cash equivalents.
Financial Highlights
31 data points| Revenue | $7.31B |
| Cost of Revenue | $3.12B |
| Gross Profit | $4.19B |
| SG&A Expenses | $2.05B |
| Operating Expenses | $5.91B |
| Operating Income | $1.41B |
| Interest Expense | $137.77M |
| Net Income | $1.32B |
| EPS (Basic) | $0.86 |
| EPS (Diluted) | $0.85 |
| Shares Outstanding (Basic) | 1.54B |
| Shares Outstanding (Diluted) | 1.55B |
Key Highlights
- 1Net sales increased by 14.8% to $7.31 billion in Q2 2008 and by 14.3% to $14.08 billion in the first six months of 2008, driven by strong segment performance and favorable currency impacts.
- 2Diluted earnings per share (EPS) were $0.85 for the quarter and $1.45 for the six months, up from $0.63 and $1.08 respectively in the prior year.
- 3The conclusion of the TAP Pharmaceutical Products Inc. joint venture resulted in Abbott acquiring the Lupron business, adding approximately $700 million in intangible assets and $350 million in goodwill, along with a contingent liability of $1.1 billion.
- 4Pharmaceutical Products segment showed significant sales growth of 16.7% in Q2 and 15.5% for the first six months, fueled by strong performance of Humira and Depakote, and the addition of Lupron sales.
- 5Operating earnings grew to $1.41 billion in Q2 and $2.55 billion in the first six months, indicating improved profitability.
- 6The company generated robust cash flow from operations of $3.06 billion for the first six months of 2008, enabling continued investment and capital returns.
- 7Abbott maintained a strong balance sheet with $3.80 billion in cash and cash equivalents and significant working capital, alongside substantial unused lines of credit.